论文部分内容阅读
目的分析预防性口服羧甲斯坦防治脑血管病后遗症患者肺部感染的临床效果,为临床防治提供依据。方法选取2012年1月-2015年1月医院脑血管病后遗症患者180例为研究对象,分为观察组与对照组,每组90例,两组患者均给予常规的康复治疗,观察组在此基础上,给予口服羧甲斯坦预防感染。结果两组患者均无失访,观察组随访时间为(11.73±0.53)月,对照组随访时间为(11.82±0.54)月,两组随访时间差异无统计学意义,随访结果显示,观察组肺部感染7例,感染率为7.78%,对照组肺部感染34例,感染率为37.78%,观察组肺部感染率明显低于对照组,差异有统计学意义(P<0.05);41例感染患者共分离病原菌50株,其中革兰阳性菌共14株,占28.00%,革兰阴性菌共34株,占68.00%,真菌2株,占4.00%。结论预防性口服羧甲斯坦防治脑血管病后遗症患者肺部感染的临床效果显著,临床上值得推广。
Objective To analyze the clinical effect of prophylactic oral administration of carbostyrs in the prevention and treatment of pulmonary infection in patients with sequelae of cerebrovascular disease and provide evidence for clinical prevention and treatment. Methods One hundred and eighty patients with sequelae of cerebrovascular disease in hospital from January 2012 to January 2015 were selected as observation group and control group, with 90 cases in each group. Both groups were given conventional rehabilitation treatment. Based on oral administration of carboxymethyst to prevent infection. Results The patients in both groups had no follow-up, the follow-up time was 11.73 ± 0.53 months in the observation group and 11.82 ± 0.54 months in the control group. There was no significant difference in the follow-up time between the two groups. The follow- The infection rate in the control group was 34.7%, the infection rate was 37.78%. The lung infection rate in the observation group was significantly lower than that in the control group (P <0.05), 41 cases A total of 50 pathogenic bacteria were isolated from infected patients, of which 14 strains were Gram-positive bacteria, accounting for 28.00%. There were 34 Gram-negative bacteria, accounting for 68.00%, 2 fungi, accounting for 4.00%. Conclusions The prophylactic oral administration of carbostyrs in the prevention and treatment of sequelae of cerebrovascular disease in patients with lung infection has a significant clinical effect, it is clinically worthy of promotion.